BioCryst Announces Additional $2,5M NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus Disease

BioCryst Pharmaceuticals BCRX today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling program and to submit an IND. This option represents an additional $2.5 million to BioCryst in order to advance the development of BCX4430 as a treatment for Marburg virus disease. NIAID, part of the National Institutes of Health, granted an initial award of $5.0 million to BioCryst in September 2013. The total funding could be up to $22.0 million over five years and advance the program through Phase 1 trials, if all contract options are exercised. “With these additional funds, BioCryst will rapidly initiate See full press release